Efficacy and Tolerability of Nasobol, an Intra-Nasal Testosterone Product, for Testosterone Replacement in Hypogonadal Men.

Trial Profile

Efficacy and Tolerability of Nasobol, an Intra-Nasal Testosterone Product, for Testosterone Replacement in Hypogonadal Men.

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Oct 2017

At a glance

  • Drugs Testosterone (Primary) ; Testosterone
  • Indications Hypogonadism
  • Focus Pharmacokinetics
  • Sponsors Acerus Pharmaceuticals
  • Most Recent Events

    • 17 Oct 2017 Trimel Pharmaceuticals Corporation changed its name to Acerus Pharmaceuticals Corporation in Sep 2015.
    • 05 Aug 2011 Trial results met the FDA's guidelines for product approval, according to a Trimel Pharmaceuticals media release.
    • 06 Aug 2010 Actual end date (May 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top